Search hospitals > Hawaii > Honolulu
Straub Clinic and Hospital
Claim this profileHonolulu, Hawaii 96813
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
304 reported clinical trials
16 medical researchers
Summary
Straub Clinic and Hospital is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Straub Clinic and Hospital is involved with conducting 304 clinical trials across 469 conditions. There are 16 research doctors associated with this hospital, such as Wade T. Kyono, Jeffrey L. Berenberg, Jared D. Acoba, and Michael Carney, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Wade T. KyonoKapiolani Medical Center for Women and Children8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
55 reported clinical trials
105 drugs studied
Jeffrey L. BerenbergStraub Clinic and Hospital2 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
29 reported clinical trials
77 drugs studied
Jared D. AcobaQueen's Medical Center2 years of reported clinical research
Studies Colon Cancer
Studies Pancreatic Cancer
18 reported clinical trials
38 drugs studied
Michael Carney, MDKapiolani Medical Center for Women and Children5 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
14 reported clinical trials
29 drugs studied
Clinical Trials running at Straub Clinic and Hospital
Lung Cancer
Breast Cancer
Ovarian Cancer
Cancer
Breast cancer
Pancreatic Cancer
Esophageal cancer
Pancreatic Carcinoma
Prostate Cancer
Testicular cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Straub Clinic and Hospital?
Straub Clinic and Hospital is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Straub Clinic and Hospital is involved with conducting 304 clinical trials across 469 conditions. There are 16 research doctors associated with this hospital, such as Wade T. Kyono, Jeffrey L. Berenberg, Jared D. Acoba, and Michael Carney, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.